PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 9461216-1 1998 FKBP12, a cis-trans prolyl isomerase that binds the immunosuppressants FK506 and rapamycin, is ubiquitously expressed and interacts with proteins in several intracellular signal transduction systems. Tacrolimus 71-76 FK506 binding protein 1a Mus musculus 0-6 9446649-1 1998 Previous studies have shown that expression of a membrane targeted chimeric protein containing the erythropoietin receptor (EpoR) cytoplasmic domain fused to the FK506-binding peptide FKBP12 allowed Ba/F3 cells to be rescued from interleukin-3 (IL-3) deprivation using a dimeric form of FK506, called FK1012. Tacrolimus 162-167 FK506 binding protein 1a Mus musculus 184-190 9446649-1 1998 Previous studies have shown that expression of a membrane targeted chimeric protein containing the erythropoietin receptor (EpoR) cytoplasmic domain fused to the FK506-binding peptide FKBP12 allowed Ba/F3 cells to be rescued from interleukin-3 (IL-3) deprivation using a dimeric form of FK506, called FK1012. Tacrolimus 287-292 FK506 binding protein 1a Mus musculus 184-190 9448138-1 1998 BACKGROUND: Tacrolimus (FK506) has potent immunosuppressive properties reflecting its ability to block the transcription of lymphokine genes in activated T cells through formation of a complex with FK506 binding protein-12, which inhibits the phosphatase activity of calcineurin. Tacrolimus 12-22 FK506 binding protein 1a Mus musculus 198-222 9448138-1 1998 BACKGROUND: Tacrolimus (FK506) has potent immunosuppressive properties reflecting its ability to block the transcription of lymphokine genes in activated T cells through formation of a complex with FK506 binding protein-12, which inhibits the phosphatase activity of calcineurin. Tacrolimus 24-29 FK506 binding protein 1a Mus musculus 198-222 7545671-4 1995 The inhibitory effect of rapamycin on serum-induced p70s6k activation and the phosphorylation of Thr229, Thr389, Ser404, and Ser411 is rescued by FK506, providing further evidence that the inhibitory effect is exerted through a complex of rapamycin-FKBP12. Tacrolimus 146-151 FK506 binding protein 1a Mus musculus 249-255 9016789-2 1997 FK506, in contrast, had no effect on DEX-induced apoptosis; moreover, an excess of FK506 reversed the potentiation of apoptosis by RAP, indicating that RAP exerts its effects through binding to FKBP. Tacrolimus 83-88 FK506 binding protein 1a Mus musculus 194-198 1382293-9 1992 The resistance of BMMCs to inhibition of Fc epsilon receptor type I-mediated increases in cytokine mRNA by FK506 is most likely due to their deficiency of FKBP12 and the related inability to inhibit the activity of calcineurin. Tacrolimus 107-112 FK506 binding protein 1a Mus musculus 155-161 7530743-2 1995 We previously associated the resistance of BMMC to FK506 with a deficiency in the expression of FK506 binding protein (FKBP) 12, a molecule that forms a complex with FK506 capable of inhibiting calcineurin phosphatase activity in vitro. Tacrolimus 51-56 FK506 binding protein 1a Mus musculus 96-117 7530743-2 1995 We previously associated the resistance of BMMC to FK506 with a deficiency in the expression of FK506 binding protein (FKBP) 12, a molecule that forms a complex with FK506 capable of inhibiting calcineurin phosphatase activity in vitro. Tacrolimus 51-56 FK506 binding protein 1a Mus musculus 119-123 7530743-2 1995 We previously associated the resistance of BMMC to FK506 with a deficiency in the expression of FK506 binding protein (FKBP) 12, a molecule that forms a complex with FK506 capable of inhibiting calcineurin phosphatase activity in vitro. Tacrolimus 96-101 FK506 binding protein 1a Mus musculus 119-123 7530743-3 1995 In this report, we establish that FKBP12 mediates FK506 inhibition of both calcineurin phosphatase activity and IgE activation-induced cytokine transcripts in a Kirsten murine sarcoma virus-immortalized mast cell line that is FKBP12 deficient. Tacrolimus 50-55 FK506 binding protein 1a Mus musculus 34-40 7530743-3 1995 In this report, we establish that FKBP12 mediates FK506 inhibition of both calcineurin phosphatase activity and IgE activation-induced cytokine transcripts in a Kirsten murine sarcoma virus-immortalized mast cell line that is FKBP12 deficient. Tacrolimus 50-55 FK506 binding protein 1a Mus musculus 226-232 7530743-4 1995 Overexpression of FKBP12 by transfection enhanced the ability of FK506 to inhibit calcineurin phosphatase activity (IC50 = 2 nM), compared with cells transfected with the expression vector alone (IC50 > 30 nM). Tacrolimus 65-70 FK506 binding protein 1a Mus musculus 18-24 7530743-5 1995 The IC50 value for FK506 inhibition of IgE activation-induced transcripts for TNF-alpha decreased from 40 nM in vector control cells to 10 nM in FKBP12 transfectants. Tacrolimus 19-24 FK506 binding protein 1a Mus musculus 145-151 7530743-8 1995 Thus, FKBP12 is the dominant cytosolic protein that mediates FK506 inhibition of TNF-alpha and IL-6 transcripts. Tacrolimus 61-66 FK506 binding protein 1a Mus musculus 6-12 7681074-7 1993 The FK506-binding immunophilin FKBP12, as well as calcineurin, are shown to be present in these cells by immunoblotting analysis. Tacrolimus 4-9 FK506 binding protein 1a Mus musculus 18-37 27190501-3 2016 Rapamycin and FK506 bind to FK506-binding proteins (FKBPs), such as FKBP12, which causes suppression of the immune system and inhibition of mTOR. Tacrolimus 14-19 FK506 binding protein 1a Mus musculus 68-74 1377606-3 1992 The structurally related drug FK506 had no effect on pp70S6K activation but at high concentrations reversed the rapamycin-induced block, confirming the requirement for the rapamycin and FK506 receptor, FKBP. Tacrolimus 30-35 FK506 binding protein 1a Mus musculus 202-206 31908154-0 2020 Tacrolimus-induced hypomagnesemia and hypercalciuria requires FKBP12 suggesting a role for calcineurin. Tacrolimus 0-10 FK506 binding protein 1a Mus musculus 62-68 31908154-5 2020 The CNI tacrolimus can inhibit calcineurin only when it binds with the immunophilin, FKBP12; we previously generated mice in which FKBP12 could be deleted along the nephron, to test whether calcineurin inhibition is involved, these mice are normal at baseline. Tacrolimus 8-18 FK506 binding protein 1a Mus musculus 85-91 31908154-8 2020 In contrast, KS-FKBP12-/- mice treated with tacrolimus were completely protected from these effects. Tacrolimus 44-54 FK506 binding protein 1a Mus musculus 16-22 30294901-3 2019 The immunophilin FKBP12 binding ligand FK506 is well known as an immunosuppressive agent by inhibiting the calcineurin expression. Tacrolimus 39-44 FK506 binding protein 1a Mus musculus 4-23 30294901-4 2019 In this study, we synthesized a series of modified compounds based on the FKBP12 binding moiety to as same as the binding structure of rapamycin and FK506 particularly. Tacrolimus 149-154 FK506 binding protein 1a Mus musculus 74-80 26432904-1 2016 Tacrolimus is a widely used immunosuppressive drug that inhibits the phosphatase calcineurin when bound to the 12 kDa FK506-binding protein (FKBP12). Tacrolimus 0-10 FK506 binding protein 1a Mus musculus 141-147 26432904-8 2016 When treated with tacrolimus, however, BP and the renal abundance of phosphorylated NCC were lower in mice lacking FKBP12 along the nephron than in control mice. Tacrolimus 18-28 FK506 binding protein 1a Mus musculus 115-121 26432904-9 2016 Mice lacking FKBP12 along the nephron also maintained a normal relationship between plasma potassium levels and the abundance of phosphorylated NCC with tacrolimus treatment. Tacrolimus 153-163 FK506 binding protein 1a Mus musculus 13-19 21430698-1 2011 Immunophilin, FK506-binding protein 12 (FK506BP), is a receptor protein for the immunosuppressive drug FK506 by the FK506BP/FK506 complex. Tacrolimus 14-19 FK506 binding protein 1a Mus musculus 40-47 22495293-2 2012 In addition to increasing transforming growth factor (TGF)-beta levels, tacrolimus inhibits calcineurin by binding to FK506-binding protein 12 (FKBP12). Tacrolimus 72-82 FK506 binding protein 1a Mus musculus 118-142 22495293-2 2012 In addition to increasing transforming growth factor (TGF)-beta levels, tacrolimus inhibits calcineurin by binding to FK506-binding protein 12 (FKBP12). Tacrolimus 72-82 FK506 binding protein 1a Mus musculus 144-150 22495293-4 2012 Here we tested whether tacrolimus binding to FKBP12 removes an inhibition of the TGF-beta receptor, allowing ligand binding, ultimately leading to receptor activation and arteriolar hyalinosis. Tacrolimus 23-33 FK506 binding protein 1a Mus musculus 45-51 21288594-1 2011 FK506 binding protein 12 (FK506BP) is an immunophilin that acts as a receptor for the immunosuppressant drug FK506. Tacrolimus 0-5 FK506 binding protein 1a Mus musculus 26-33 21430698-1 2011 Immunophilin, FK506-binding protein 12 (FK506BP), is a receptor protein for the immunosuppressive drug FK506 by the FK506BP/FK506 complex. Tacrolimus 14-19 FK506 binding protein 1a Mus musculus 116-123 21430698-1 2011 Immunophilin, FK506-binding protein 12 (FK506BP), is a receptor protein for the immunosuppressive drug FK506 by the FK506BP/FK506 complex. Tacrolimus 40-45 FK506 binding protein 1a Mus musculus 14-38 21430698-1 2011 Immunophilin, FK506-binding protein 12 (FK506BP), is a receptor protein for the immunosuppressive drug FK506 by the FK506BP/FK506 complex. Tacrolimus 40-45 FK506 binding protein 1a Mus musculus 116-123 21163525-5 2011 Furthermore, acute treatment with CsA to inhibit CypD modulation of mitochondrial Ca(2+) buffering, or with FK506 to inhibit FKBP12 interaction with inositol-trisphosphate receptor of the endoplasmic reticulum, led to similar reductive effects on astrocytic Ca(cyt)(2+) dynamics, but also to an enhanced Ca(2+)-dependent exocytotic release of glutamate in wild-type astrocytes. Tacrolimus 108-113 FK506 binding protein 1a Mus musculus 125-131 21518963-1 2011 Patients treated with the immunosuppressive drug tacrolimus (FK506), which binds FK506 binding protein 12 (FKBP12) and then inhibits the calcium-dependent phosphatase calcineurin, exhibit decreased regulatory T cells, endothelial dysfunction, and hypertension; however, the mechanisms and whether altered T-cell polarization play a role are unknown. Tacrolimus 49-59 FK506 binding protein 1a Mus musculus 81-105 21518963-1 2011 Patients treated with the immunosuppressive drug tacrolimus (FK506), which binds FK506 binding protein 12 (FKBP12) and then inhibits the calcium-dependent phosphatase calcineurin, exhibit decreased regulatory T cells, endothelial dysfunction, and hypertension; however, the mechanisms and whether altered T-cell polarization play a role are unknown. Tacrolimus 49-59 FK506 binding protein 1a Mus musculus 107-113 21518963-1 2011 Patients treated with the immunosuppressive drug tacrolimus (FK506), which binds FK506 binding protein 12 (FKBP12) and then inhibits the calcium-dependent phosphatase calcineurin, exhibit decreased regulatory T cells, endothelial dysfunction, and hypertension; however, the mechanisms and whether altered T-cell polarization play a role are unknown. Tacrolimus 61-66 FK506 binding protein 1a Mus musculus 81-105 21518963-1 2011 Patients treated with the immunosuppressive drug tacrolimus (FK506), which binds FK506 binding protein 12 (FKBP12) and then inhibits the calcium-dependent phosphatase calcineurin, exhibit decreased regulatory T cells, endothelial dysfunction, and hypertension; however, the mechanisms and whether altered T-cell polarization play a role are unknown. Tacrolimus 61-66 FK506 binding protein 1a Mus musculus 107-113 17478757-1 2007 OBJECTIVES: FK506 Binding Protein 12 and its related isoform 12.6 (FKBP12/12.6) stabilize a closed state of intracellular Ca2+ release channels (ryanodine receptors [RyRs]), and in myocytes removal of FKBP12/12.6 from RyRs alters intracellular Ca2+ levels. Tacrolimus 12-17 FK506 binding protein 1a Mus musculus 67-73 20164329-8 2010 Thus, FK506 likely targets FKBP members in the cell culture model. Tacrolimus 6-11 FK506 binding protein 1a Mus musculus 27-31 19177155-0 2009 Tacrolimus reduces nitric oxide synthase function by binding to FKBP rather than by its calcineurin effect. Tacrolimus 0-10 FK506 binding protein 1a Mus musculus 64-68 19177155-7 2009 Since it is known that the FK506 binding protein (FKBP12/12.6) interacts with the ryanodine receptor to regulate calcium release, we propose this as the mechanism by which tacrolimus alters intracellular calcium and endothelial nitric oxide synthase rather than by its effect on calcineurin. Tacrolimus 172-182 FK506 binding protein 1a Mus musculus 50-56 20674565-2 2010 Tacrolimus forms a complex with FK506 binding protein (FKBP), and Cys A forms a complex with cyclophilin. Tacrolimus 0-10 FK506 binding protein 1a Mus musculus 32-53 20674565-2 2010 Tacrolimus forms a complex with FK506 binding protein (FKBP), and Cys A forms a complex with cyclophilin. Tacrolimus 0-10 FK506 binding protein 1a Mus musculus 55-59 17478757-1 2007 OBJECTIVES: FK506 Binding Protein 12 and its related isoform 12.6 (FKBP12/12.6) stabilize a closed state of intracellular Ca2+ release channels (ryanodine receptors [RyRs]), and in myocytes removal of FKBP12/12.6 from RyRs alters intracellular Ca2+ levels. Tacrolimus 12-17 FK506 binding protein 1a Mus musculus 201-207 17478757-2 2007 The immunosuppressive drugs rapamycin and FK506 bind and displace FKBP12/12.6 from RyRs, and can also cause endothelial dysfunction and hypertension. Tacrolimus 42-47 FK506 binding protein 1a Mus musculus 66-72 17478757-9 2007 CONCLUSIONS: Complete removal of FKBP12 and 12.6 from endothelial RyRs induces an intracellular Ca2+ leak which may contribute to the pathogenesis of endothelial dysfunction and hypertension caused by rapamycin or FK506. Tacrolimus 214-219 FK506 binding protein 1a Mus musculus 33-39 11907581-1 2002 FK506 binding proteins 12 and 12.6 (FKBP12 and FKBP12.6) are intracellular receptors for the immunosuppressant drug FK506 (ref. Tacrolimus 0-5 FK506 binding protein 1a Mus musculus 36-42 12085010-0 2002 FKBP12 is the only FK506 binding protein mediating T-cell inhibition by the immunosuppressant FK506. Tacrolimus 19-24 FK506 binding protein 1a Mus musculus 0-6 12085010-0 2002 FKBP12 is the only FK506 binding protein mediating T-cell inhibition by the immunosuppressant FK506. Tacrolimus 94-99 FK506 binding protein 1a Mus musculus 0-6 12085010-7 2002 RESULTS: We found that growth inhibition induced by FK506 is abolished in FKBP12-deficient cells but not in FKBP12.6-deficient cells. Tacrolimus 52-57 FK506 binding protein 1a Mus musculus 74-80 12414688-6 2002 This effect was similar to those of FK506 and rapamycin, two drugs known to cause dissociation of FKBP12 from RyR. Tacrolimus 36-41 FK506 binding protein 1a Mus musculus 98-104 11907581-1 2002 FK506 binding proteins 12 and 12.6 (FKBP12 and FKBP12.6) are intracellular receptors for the immunosuppressant drug FK506 (ref. Tacrolimus 116-121 FK506 binding protein 1a Mus musculus 36-42 11171588-12 2001 FK-506, an inhibitor of FKBP12/IP(3) receptor interactions, had no effect on the rise in basal Ca(2+) but blocked the inhibitory effects of increased basal Ca(2+) and ACh on Ca(2+) transients. Tacrolimus 0-6 FK506 binding protein 1a Mus musculus 24-30 11890899-1 2002 FK506 (Tacrolimus) and cyclosporin A exert their immunosuppressive effects via a common mechanism, calcineurin inhibition, after binding to intracellular proteins termed immunophilins: FK506-binding protein (FKBP) and cyclophilin. Tacrolimus 0-5 FK506 binding protein 1a Mus musculus 185-206 11890899-1 2002 FK506 (Tacrolimus) and cyclosporin A exert their immunosuppressive effects via a common mechanism, calcineurin inhibition, after binding to intracellular proteins termed immunophilins: FK506-binding protein (FKBP) and cyclophilin. Tacrolimus 0-5 FK506 binding protein 1a Mus musculus 208-212 11890899-1 2002 FK506 (Tacrolimus) and cyclosporin A exert their immunosuppressive effects via a common mechanism, calcineurin inhibition, after binding to intracellular proteins termed immunophilins: FK506-binding protein (FKBP) and cyclophilin. Tacrolimus 7-17 FK506 binding protein 1a Mus musculus 185-206 11890899-1 2002 FK506 (Tacrolimus) and cyclosporin A exert their immunosuppressive effects via a common mechanism, calcineurin inhibition, after binding to intracellular proteins termed immunophilins: FK506-binding protein (FKBP) and cyclophilin. Tacrolimus 7-17 FK506 binding protein 1a Mus musculus 208-212 11890899-4 2002 Rapamycin, an immunosuppressant that binds to FKBP, antagonized the effect of FK506. Tacrolimus 78-83 FK506 binding protein 1a Mus musculus 46-50 11890899-6 2002 Taken together, these results suggest that FK506 induces chondrogenic differentiation of ATDC5 cells via a calcineurin-independent mechanism, after binding to FKBP. Tacrolimus 43-48 FK506 binding protein 1a Mus musculus 159-163 10531391-5 1999 Myoblasts and myotubes of C2-C12 cells express similar amounts of cyclophilin A and FKBP12, immunophilins known to be intracellular-binding targets for CsA and tacrolimus, respectively. Tacrolimus 160-170 FK506 binding protein 1a Mus musculus 84-90 11226255-1 2001 FKBP12, the 12-kDa FK506-binding protein, is a ubiquitous abundant protein that acts as a receptor for the immunosuppressant drug FK506, binds tightly to intracellular calcium release channels and to the transforming growth factor beta (TGF-beta) type I receptor. Tacrolimus 19-24 FK506 binding protein 1a Mus musculus 0-6 10710358-7 2000 Both FK-506 and rapamycin are known to target the immunophilin FKBP12. Tacrolimus 5-11 FK506 binding protein 1a Mus musculus 50-69 10336507-2 1999 Here, we show that FK506 maintains its neurotrophic activity in primary hippocampal cell cultures from FKBP-12 knockout mice. Tacrolimus 19-24 FK506 binding protein 1a Mus musculus 103-110